Modular Medical Secures PBM Deals for Pivot Pump
Agreements with all three largest pharmacy benefit managers aim to ease insulin pump access ahead of Pivot's full commercial launch.
Updated on Nov. 19, 2026 in Healthcare

Modular Medical, Inc. (NASDAQ: MODD) has entered agreements with the remaining two of the nation's three largest pharmacy benefit managers (PBMs) for its Pivot tubeless patch pump, following earlier agreements. The company is preparing for Pivot's full commercial launch.
Why it matters
The three largest PBMs collectively cover more than 182 million lives and process about 80% of U.S. prescription claims, so these agreements could influence whether patients can access the device. Coverage for any individual patient remains subject to the formulary decisions and benefit design of their health plan.
The three largest PBMs cover more than 182 million lives and process approximately 80% of U.S. prescription claims, according to Drug Channels Institute estimates. Individual patient coverage will depend on each health plan's formulary decisions and benefit design.
The players
Modular Medical, Inc. (NASDAQ: MODD)
A commercial-stage medical device company based in San Diego, California, developing the Pivot tubeless patch pump for insulin delivery.
The details
Modular Medical announced agreements with the remaining two of the three largest PBMs, adding to agreements already in place with all three. Pivot is designed as a simplified approach to insulin delivery for people who require intensive insulin therapy.
Timeline
November 19, 2026: Modular Medical announced the PBM agreements for Pivot.
Over the coming year: Commercial rollout of Pivot is expected.
Industry Landscape
Drug Channels Institute estimates the top three PBMs consistently process 80% of equivalent U.S. prescription claims, making their formulary decisions a gatekeeper for new device access. Modular Medical's agreements with all three position Pivot to reach the bulk of insured patients as it prepares its commercial rollout.
Patients interested in Pivot should check with their health plan, since formulary decisions determine whether the pump is covered. Coverage gaps can keep some people on multiple daily injections rather than advanced pump therapy.
The takeaway
Access through pharmacy benefit managers is often as decisive as clinical performance for new insulin devices. Patients weighing a switch should confirm coverage with their plan before committing to a device.
Further reading
Explore more Healthcare news on how insurance and pharmacy benefit structures shape access to medical devices.
Source note: This article includes information reported by Hawaii Telegraph.






